[ad_1]
A photographic illustration featuring a medical syringe. Biomed, a Polish biotechnology company based in Lublin, … [+]
Our indicative theme of Coronavirus Vaccine Stocks – which includes a diverse set of US-based pharmaceutical and biotech stocks that are working on Covid-19 vaccines – has risen more than 670% so far this year, on an equally weighted basis, compared to the S&P 500 which has gained almost 3% during the same period. While the broader markets have seen a sell-off over the past week, led by tech stocks, the US Covid vaccine players have remained largely stable as they continue to move rapidly forward with trials. , and clinical data on late-stage trials are likely to leak as early as October. On the other hand, the Oxford-Astrazeneca vaccine (which is not part of our topic) has also faced setbacks, as an illness was reported in two participants in the UK. While this might be unfortunate, investors could see this as positive for other vaccine players considering that the Oxford vaccine is considered one of the first in the race. Here’s a little more about the companies in our topic of coronavirus vaccine stocks and relative performance.
Novavax, a late-stage biotech company dedicated to vaccine development, has seen its stocks increase by more than 2,400% to date, fueled by its Covid-19 vaccine development work. The stock is back 176% since the end of 2018. The company’s candidate vaccine is currently in phase 2 trials.
Trephis
NVAX
Moderna, a clinical-stage biotech that is conducting phase 3 trials of a Covid-19 vaccine, has seen its shares rebound by 240% this year, but is still down about -30% from its highs of July. The company is likely to apply for emergency authorization for high-risk groups if its candidate demonstrates an efficacy of at least 70%. (Related: How Much Could a Covid-19 Vaccine Add to Moderna’s EPS?)
Johnson & Johnson announced Wednesday that it was entering the final stage of Phase 3 of its clinical trial of the Covid-19 vaccine, seeking to enroll up to 60k participants in the US and abroad. The stock is nearly flat year-to-date and is up about 17% since 2018. (Related: Is Johnson & Johnson a better bet than Merck?)
Pfizer: The major drugmaker, which is working with German partner BioNTech on a Covid-19 vaccine, is down -6% to date. The stock is also down about -13% since 2018. Phase 3 trials for the vaccine began in the US in July and the company expects to have early results on efficacy around October. (related: Pfizer seems less expensive compared to Roche)
What if you are looking for a more balanced portfolio? Here is a high-quality wallet to beat the market, with more than 100% return since 2016, compared to roughly 50% for the S&P 500. Comprised of companies with strong revenue growth, healthy earnings, lots of cash and low risk, it has outperformed the broader market year over year , constantly.
See everything Trefis price estimates Y to download Trefis Data here
What’s behind Trefis? See how you are driving a new collaboration and what if CFO and finance teams | Product, R&D and marketing teams
